Cancer genomics: from discovery science to personalized medicine

被引：439

作者：

Chin, Lynda ^{[1
,2
,3
]}

Andersen, Jannik N. ^{[1
]}

Futreal, P. Andrew ^{[4
]}

机构：

[1] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA

[3] Broad Inst MIT & Harvard, Cambridge, MA USA

[4] Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton, England

来源：

NATURE MEDICINE | 2011年 / 17卷 / 03期

关键词：

GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; ANAPLASTIC LYMPHOMA KINASE; EML4-ALK FUSION GENE; SOMATIC MUTATIONS; ALK KINASE; ACTIVATING MUTATIONS; MONOCLONAL-ANTIBODY; FGFR2; MUTATIONS; PIK3CA GENE;

D O I：

10.1038/nm.2323

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Recent advances in genome technologies and the ensuing outpouring of genomic information related to cancer have accelerated the convergence of discovery science and clinical medicine. Successful examples of translating cancer genomics into therapeutics and diagnostics reinforce its potential to make possible personalized cancer medicine. However, the bottlenecks along the path of converting a genome discovery into a tangible clinical endpoint are numerous and formidable. In this Perspective, we emphasize the importance of establishing the biological relevance of a cancer genomic discovery in realizing its clinical potential and discuss some of the major obstacles to moving from the bench to the bedside.

引用

页码：297 / 303

页数：7

共 67 条

[1] American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy [J].

Allegra, Carmen J. ;

Jessup, J. Milburn ;

Somerfield, Mark R. ;

Hamilton, Stanley R. ;

Hammond, Elizabeth H. ;

Hayes, Daniel F. ;

McAllister, Pamela K. ;

Morton, Roscoe F. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2091-2096

[2] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[3] The PIK3CA gene is mutated with high frequency in human breast cancers [J].

Bachman, KE ;

Argani, P ;

Samuels, Y ;

Silliman, N ;

Ptak, J ;

Szabo, S ;

Konishi, H ;

Karakas, B ;

Blair, BG ;

Lin, C ;

Peters, BA ;

Velculescu, VE ;

Park, BH .

CANCER BIOLOGY & THERAPY, 2004, 3 (08) :772-775

[4] AMINO-ACID SUBSTITUTIONS AT CODON-13 OF THE N-RAS ONCOGENE IN HUMAN ACUTE MYELOID-LEUKEMIA [J].

BOS, JL ;

TOKSOZ, D ;

MARSHALL, CJ ;

VERLAANDEVRIES, M ;

VEENEMAN, GH ;

VANDEREB, AJ ;

VANBOOM, JH ;

JANSSEN, JWG ;

STEENVOORDEN, ACM .

NATURE, 1985, 315 (6022) :726-730

[5] PI3K and mTOR inhibitors - a new generation of targeted anticancer agents [J].

Brachmann, Saskia ;

Fritsch, Christine ;

Maira, Saveur-Michel ;

Garcia-Echeverria, Carlos .

CURRENT OPINION IN CELL BIOLOGY, 2009, 21 (02) :194-198

[6] Mutation of the PIK3CA gene in ovarian and breast cancer [J].

Campbell, IG ;

Russell, SE ;

Choong, DYH ;

Montgomery, KG ;

Ciavarella, ML ;

Hooi, CSF ;

Cristiano, BE ;

Pearson, RB ;

Phillips, WA .

CANCER RESEARCH, 2004, 64 (21) :7678-7681

[7] ACTIVATION OF KI-RAS 2 GENE IN HUMAN-COLON AND LUNG CARCINOMAS BY 2 DIFFERENT POINT MUTATIONS [J].

CAPON, DJ ;

SEEBURG, PH ;

MCGRATH, JP ;

HAYFLICK, JS ;

EDMAN, U ;

LEVINSON, AD ;

GOEDDEL, DV .

NATURE, 1983, 304 (5926) :507-513

[8] Oncogenic mutations of ALK kinase in neuroblastoma [J].

Chen, Yuyan ;

Takita, Junko ;

Choi, Young Lim ;

Kato, Motohiro ;

Ohira, Miki ;

Sanada, Masashi ;

Wang, Lili ;

Soda, Manabu ;

Kikuchi, Akira ;

Igarashi, Takashi ;

Nakagawara, Akira ;

Hayashi, Yasuhide ;

Mano, Hiroyuki ;

Ogawa, Seishi .

NATURE, 2008, 455 (7215) :971-U56

[9] Comprehensive genomic characterization defines human glioblastoma genes and core pathways [J].

Chin, L. ;

Meyerson, M. ;

Aldape, K. ;

Bigner, D. ;

Mikkelsen, T. ;

VandenBerg, S. ;

Kahn, A. ;

Penny, R. ;

Ferguson, M. L. ;

Gerhard, D. S. ;

Getz, G. ;

Brennan, C. ;

Taylor, B. S. ;

Winckler, W. ;

Park, P. ;

Ladanyi, M. ;

Hoadley, K. A. ;

Verhaak, R. G. W. ;

Hayes, D. N. ;

Spellman, Paul T. ;

Absher, D. ;

Weir, B. A. ;

Ding, L. ;

Wheeler, D. ;

Lawrence, M. S. ;

Cibulskis, K. ;

Mardis, E. ;

Zhang, Jinghui ;

Wilson, R. K. ;

Donehower, L. ;

Wheeler, D. A. ;

Purdom, E. ;

Wallis, J. ;

Laird, P. W. ;

Herman, J. G. ;

Schuebel, K. E. ;

Weisenberger, D. J. ;

Baylin, S. B. ;

Schultz, N. ;

Yao, Jun ;

Wiedemeyer, R. ;

Weinstein, J. ;

Sander, C. ;

Gibbs, R. A. ;

Gray, J. ;

Kucherlapati, R. ;

Lander, E. S. ;

Myers, R. M. ;

Perou, C. M. ;

McLendon, Roger .

NATURE, 2008, 455 (7216) :1061-1068

[10] Essential role for oncogenic Ras in tumour maintenance [J].

Chin, L ;

Tam, A ;

Pomerantz, J ;

Wong, M ;

Holash, J ;

Bardeesy, N ;

Shen, Q ;

O'Hagan, R ;

Pantginis, J ;

Zhou, H ;

Horner, JW ;

Cordon-Cardo, C ;

Yancopoulos, GD ;

DePinho, RA .

NATURE, 1999, 400 (6743) :468-472

← 1 2 3 4 5 6 7 →